GnuBIO Unveils the World's First Prototype Fully Integrated DNA Sequencer at the Association of Molecular Pathology Conference
GnuBIO, Inc. (GnuBIO), www.gnubio.com a pioneer in the Desktop DNA sequencing market, announced today that it will unveil the prototype of the world's first fully integrated DNA sequencer (the K-cup coffee cartridge model of DNA sequencing) at the Association of Molecular Pathology (AMP) conference, booth #330, from October 25th – October 27th.
“The prototype system that we will unveil at AMP has the exact dimensions and configurations of both the beta and commercial system that will be launched shortly. The prototype is built around optics, electronics and process controls that are installed within our systems running in house”, stated Sepehr Kiani, Executive Vice President of Product Development. Kiani continued, “The prototype will give the world its first glimpse of a fully integrated workflow, whereby a user can simply inject a DNA sample into a cartridge, load the cartridge in the system, press the ‘Run' button, and walk away.”
The GnuBIO system has a completely integrated workflow, inclusive of genomic selection, amplification, sequencing and real time informatics (assembly and variant calling), allowing researchers and clinicians to simply inject genomic DNA, and walk away – with data provided on the targeted regions within a few hours. The commercial system is anticipated to sell for $50K USD, and will not require any additional sample preparation systems or informatics clusters.
“By eliminating the sample preparation procedure of DNA sequencing, allowing minimally trained technicians to simply inject genomic DNA and walk away, GnuBIO www.gnubio.com is propagating a powerful technology that will have a profound effect on both patient care as well as the overall healthcare system,” stated John Boyce, President, CEO, and Co-Founder. “The GnuBIO system will allow researchers and clinicians to run one or many samples at a time, at a very low investment – thereby obviating the need for a clinical laboratory to wait until it has tens or hundreds of samples to amortize the cost, and allow diagnosis in hours as opposed to days or weeks,” Boyce continued.
GnuBIO, Inc. (www.gnubio.com) is a private company and a pioneer in the field of scalable DNA sequencing technology for the Diagnostic and Applied Markets. Utilizing its proprietary microfluidic and emulsion technologies, GnuBIO will work within these markets to develop nucleic acid analysis based systems that scale as a function of both patient sample and genomic region. The GnuBIO system has the capability of running numbers of samples that are in line with diagnostic and applied market requirements for a cost that is orders of magnitude lower than with current technology.
The GnuBIO system has a completely integrated workflow, inclusive of genomic selection, amplification, sequencing and real time informatics (assembly and variant calling), allowing researchers and clinicians to simply inject genomic DNA, and walk away – with data on the target regions in a few hours.
Susie Truong Harborth, 617-446-6742
Chief Financial Officer